Instruction for use: RutacidI want this, give me price
Active substance Hydrotalcite
ATX Code A02AD04 Hydrotalcite
Nosological classification (ICD-10)
K21.0 Gastro-oesophageal reflux with oesophagitis
Reflux gastritis, Reflux esophagitis, Erosive and ulcerative esophagitis
K25 Gastric ulcer
Helicobacter pylori, Pain syndrome in gastric ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, Inflammation of the gastric mucosa, Inflammation of the gastrointestinal mucosa, Benign gastric ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Aggravation gastroduodenita on the background of peptic ulcer, Exacerbation of peptic ulcer, The aggravation of gastric ulcer, The organic gastrointestinal disease, Peptic ulcer of the stomach and duodenum, Postoperative gastric ulcer, Recurrent ulcers, Symptomatic gastric ulcers, Chronic inflammatory disease of the upper gastrointestinal tract, associated with Helicobacter pylori, Helicobacter pylori eradication, Erosive and ulcerative lesions of the stomach, Erosive lesions of the stomach, The erosion of the gastric mucosa, Peptic ulcer disease, Stomach ulcer, Gastric lesion, Ulcerative lesions of the stomach, Symptomatic ulcers of the stomach and duodenum
K26 Duodenal Ulcer
Pain with duodenal ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Exacerbation of peptic ulcer, The worsening of duodenal ulcer, Peptic ulcer of the stomach and duodenum, Relapse of duodenal ulcers, Symptomatic ulcers of the stomach and duodenum, Helicobacter pylori eradication, Erosive and ulcerative lesions of the duodenum, Erosive-ulcerative lesions of duodenal ulcers associated with Helicobacter pylori, Erosive lesions of the duodenum, Duodenal ulcer, Ulcerative lesions of the duodenum]
K29.7 Unspecified gastritis
Gastritis with low acidityá Gastritisá Gastritis with a normal secretory functionáGastritisá Erosive gastritis
K31.8.2 * Hyperacidity of gastric juice
Pathological hypersecretion, Hyperacid indigestion, Hyperadic states, Increased secretion of gastric juice, Increased acid formation, Hyperacidosis,Hyper secretion of gastric juice, Increased acidity of gastric juice, High acidity
Tablets chewing 1 tab.
hydrotalcite 500 mg
auxiliary substances: mannitol - 836 mg; sodium saccharinate - 0.6 mg; sodium carboxymethyl starch - 12 mg; talc - 35 mg; magnesium stearate - 14 mg; peppermint flavor - 2.4 mg
Description of dosage form
Round tablets white or almost white with a bevelled edge and a slight minty odor.
Pharmacological action - antacid.
The hydrotalcite has a stratified-mesh structure with a low content of aluminum and magnesium. The release of aluminum and magnesium ions occurs gradually depending on the pH of the gastric juice. The drug provides a fast and long-lasting neutralization of hydrochloric acid with maintaining the pH close to normal. Has a protective effect on the mucous membrane of the stomach. Reduces the proteolytic activity of pepsin, binds bile acids.
The release of magnesium and aluminum ions occurs in the stomach gradually, depending on the pH value. Absorption of the drug occurs in the small intestine. After ingestion, the content of magnesium and aluminum ions in the blood plasma temporarily increases, but no penetration into the nerve and bone tissue occurs (with normal kidney function). The absorbed part is excreted by the kidneys.
acute gastritis, chronic gastritis with increased secretory function in the exacerbation phase;
acute and chronic duodenitis;
peptic ulcer of the stomach and duodenum;
discomfort and epigastric pain, heartburn, acidic eructations after dietary errors, excessive alcohol consumption, and medication.
increased sensitivity to hydrotalcite;
children's age (up to 6 years).
With caution: chronic renal failure, hypophosphatemia.
pregnancy and lactation
Confirmed data on the undesirable effects of hydrotalcite during pregnancy and breastfeeding there. The use of the drug during pregnancy is possible if the potential benefit to the mother exceeds the possible risk to the fetus. The drug does not penetrate into breast milk, so breast-feeding women can take the drug.
When taking the drug, side effects occur rarely. Allergic reactions, diarrhea, eructation are possible.
Rutacid® reduces the absorption of tetracycline antibiotics, fluoroquinolones (ciprofloxacin, ofloxacin), coumarins, iron preparations.
Dosing and Administration
Inside, thoroughly chewing.
Adults and children over 12 years of age: 1-2 tablets. 1 hour after meals 3-4 times a day and at bedtime.
Children from 6 to 12 years: 1 table. 2 times a day.
Treatment should be continued for 4 weeks.
There were no cases of overdose with Rutacid®.
The interval between the use of the drug and other drugs should be at least 1-2 hours.
It is not recommended to use the drug Rutacid® simultaneously with acid-containing beverages (juices, wine).
The drug Rutacid® does not contain sucrose, therefore it can be used by patients with diabetes mellitus.
Polyols (mannitol) can cause diarrhea.
Influence on the ability to drive and other mechanisms. Does not affect.
Form of issue
Tablets are chewable, 500 mg. For 10 tab. in the blister pack. For 2 or 6 blisters packaged in a cardboard box.
Conditions of leave from pharmacies
At a temperature not exceeding 30 ° C.
Keep out of the reach of children.
Do not use after the expiry date printed on the package.